CYP2D6 rs7770370: Pharmacogenomics and Drug Metabolism

What each genotype means

Genomic Location and Variant Characteristics

The single-nucleotide polymorphism rs7770370 is situated on chromosome 22q13.2 within the CYP2D gene cluster, which contains the active CYP2D6 gene alongside highly homologous pseudogenes CYP2D7 and CYP2D8. This specific variant resides within a non-coding intronic region of CYP2D6. Because it does not alter an amino acid sequence directly, rs7770370 is primarily evaluated as a tag SNP or linkage marker that may co-segregate with functional haplotype alleles. The genomic architecture of the CYP2D6 locus is notoriously complex, characterized by dense sequence homology, single-nucleotide variations, and frequent structural rearrangements such as gene duplications and deletions. Consequently, isolated intronic variants like rs7770370 are typically contextualized by their proximity to established functional star alleles defined by international pharmacogenomic consortia.

The Biological Function of CYP2D6

The CYP2D6 gene encodes cytochrome P450 family 2 subfamily D member 6, a membrane-bound hepatic enzyme responsible for the phase I oxidative metabolism of roughly 20 to 25 percent of all clinically prescribed medications. Despite constituting a modest fraction of total hepatic cytochrome P450 protein content, CYP2D6 plays a pivotal role in bioactivating prodrugs into active therapeutic compounds and clearing active molecules into excretable forms. Key substrates metabolized through CYP2D6 pathways include opioids such as codeine and tramadol, selective estrogen receptor modulators like tamoxifen, tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, and antiarrhythmics. Individual enzyme capacity spans a wide spectrum, historically categorized into poor, intermediate, normal, and ultrarapid metabolizer phenotypes based on inherited genetic variation.

Research Associations and Evidence Strength

In observational pharmacogenomic studies, rs7770370 has been investigated for potential correlations with systemic drug exposure and conversion rates, particularly for tamoxifen bioactivation into potent anti-estrogen metabolites like endoxifen, and the O-demethylation of codeine into morphine. However, the overall strength of evidence directly tying rs7770370 to altered drug efficacy or adverse outcomes is classified as limited. In modern clinical pharmacogenetics, major consortium guidelines—including those from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB—rely on comprehensive star-allele definitions (such as CYP2D6*4, *10, or *41) and copy number variations rather than standalone intronic markers. Because rs7770370 often co-occurs with other variants on specific ancestral haplotype backgrounds, isolating its individual biological effect remains challenging.

Navigating Pharmacogenomic Results Responsibly

Identifying an individual genotype at rs7770370 provides educational insight into genomic diversity across the CYP2D locus, but it cannot be used on its own to determine clinical drug response or replace comprehensive clinical phenotyping. Commercial sequencing platforms that report individual SNPs frequently omit critical structural variations, such as full gene deletions (*5) or multi-copy duplications, which heavily shape real-world enzyme activity. Patients should never initiate, discontinue, or alter the dosage of any prescribed medication based on direct-to-consumer genetic readouts. Decisions regarding drug choice and dose adjustments require consultation with a licensed physician or clinical pharmacogenomics specialist, who can interpret genetic findings within the context of validated clinical guidelines, concomitant medications, liver function, and overall clinical history.

Frequently asked questions

Sources & further reading

Related variants in CYP2D6